



Clinical Development Partnerships

Releasing the untapped potential in cancer drug development



Cancer Research
Technology





Working with Clinical Development Partnerships

Key Features

- Targeted at leading pharma and biotech
- Bringing new life to deprioritised cancer agents
- Early clinical development at no cost to the company
- Performed through a world class clinical trials network
- Project undertaken on a shared risk-reward basis

Benefits

- Company retains rights to intellectual property and a first option to clinical data
- CDP delivers simple, rapid contractual arrangements and support for knowledge transfer
- CDP is a dedicated team within the largest independent cancer research organisation in the world



Clinical Development Partnerships

Clinical Development Partnerships (CDP) is a joint initiative launched by Cancer Research UK in collaboration with its development and commercialisation company Cancer Research Technology Limited. CDP aims to increase the number of successful new treatments for cancer patients by taking more compounds into clinical development.

The programme is primarily **targeted at leading pharmaceutical and biotechnology companies** who have large pipelines and are forced to prioritise which agents they take into clinical development. Clinical trials are inherently expensive and rigorous selection criteria are applied to potential agents. As a result many promising cancer agents have been shelved and their clinical development discontinued.

CDP offers companies an alternative path for clinical development **bringing new life to deprioritised cancer agents**. It is a unique opportunity for companies to maximise the value of their shelved assets and work with Cancer Research UK, the largest independent organisation dedicated to cancer research in the world, to develop new agents for the benefit of cancer patients.

Primary Focus:


- Novel targeted small molecules and biological therapeutics

Secondary Focus:

- Repurposed agents, improved derivatives, combination studies

CDP Application Process

(Timelines are approximate and assume no preclinical work is required)



Phase I and II Clinical Trials

CDP will source promising cancer agents and conduct **early clinical development at no cost to the company**. Phase I and II clinical trials will be sponsored and co-ordinated by Cancer Research UK's Drug Development Office (DDO).

Cancer Research UK has an impressive record in the development of novel treatments for cancer. Since the DDO was established in 1982, it has taken over 100 agents into Phase I/II studies of which four, including Temodal® have so far reached the market. The DDO has experienced in-house staff for managing, monitoring and reporting the trials and dealing with regulatory issues. All studies are conducted in line with current legal and regulatory requirements. Non-clinical safety studies, formulation development and final-product

manufacture can also be undertaken if required.

Potential drug candidates identified by CDP will be reviewed in confidence and an application with a proposed trial outline submitted to the New Agents Committee (NAC), a funding committee of Cancer Research UK. The clinical trials will be **performed through a world class clinical trials network** of Phase I and II expert centres throughout the UK under the Sponsorship of Cancer Research UK. Access to leading edge technologies and expert scientists in the centres ensures that all studies produce quality proof of principle data. Updates on the clinical trial will be provided to the company during the course of the study and a final clinical report prepared on completion.

DDO Key Facts:

- Experienced in the development of small molecules and biological therapeutics
- Established network of leading scientists and oncologists
- 100 agents taken into Phase I/II clinical trials
- 4 agents taken to registration by companies (including Temodal®)
- >50% of trials undertaken on company agents
- Drug formulation and biotherapeutic development capability

Business Model

Companies wishing to work with CDP will enter into a Clinical Trial & Option Agreement with Cancer Research UK and Cancer Research Technology. The negotiation and drafting of agreements is co-ordinated through Cancer Research Technology.

Cancer Research Technology was established in 1982 and has an enviable track record of commercial partnerships including research collaborations, licensing, joint ventures and start up companies. Cancer Research Technology has its own internal legal team to ensure simplified and rapid transactions. In order to minimise the legal agreement framework for CDP, both the clinical and commercial aspects of the trial have been incorporated into one Clinical Trial & Option Agreement. This template will be

used as a starting point for commercial negotiations.

The unique feature of CDP compared to other licensing strategies is that the **projects are undertaken on a shared risk-reward basis**. The company retains the rights to the existing intellectual property and a first option to the clinical data. An appropriate revenue share to CDP will be negotiated to reflect the additional value the clinical trial data have added to the product. The revenue share may be further broken down into standard licence terms in the event the company takes the product forward themselves rather than through a licensee.

www.cancer-technology.com

Key Features of the Clinical Trial & Option Agreement:

- Company grants Cancer Research UK a licence to undertake the clinical trial
- Cancer Research UK undertakes and owns data generated from the clinical trial
- Company retains rights to existing intellectual property and a first option to clinical data
- CDP has the right to develop the product if the option is not exercised
- Company and CDP receive a revenue share commensurate with the value they have added to the project

Contact Us

Website:

www.clinicalpartnerships.com

Enquiries address:

enquiries@clinicalpartnerships.com

Cancer Research UK working with its development and commercialisation company, Cancer Research Technology to increase the number of agents in clinical trials for cancer.



Together we will beat cancer